Levoxa (Levofloxacin)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes that control DNA supercoiling and replication. Inhibiting these targets stops bacterial DNA synthesis and transcription, leading to rapid bacterial cell death and clearance of the infection.

The dosage of Levoxa is determined by the prescribing clinician based on the infection type, severity, patient age, weight, and renal function. Healthcare providers select the appropriate strength, frequency, and treatment duration to achieve optimal therapeutic outcomes.

Levoxa’s safety in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit outweighs the possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Levoxa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Levoxa (levofloxacin) offers a broad spectrum of activity against both Gram‑positive and Gram‑negative bacteria, often with once‑daily dosing, which can be more convenient than many beta‑lactams or macrolides. However, fluoroquinolones carry specific safety warnings, such as tendon toxicity and QT prolongation, that may influence the choice of therapy.

Levoxa should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Levoxa is taken orally, usually with a full glass of water. It can be taken with or without food, but antacids or mineral supplements should be spaced at least two hours apart to avoid reduced absorption.

Serious risks include tendon rupture (especially in older adults), QT interval prolongation leading to arrhythmias, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and peripheral neuropathy. Patients should seek immediate medical attention if they experience sudden tendon pain, palpitations, severe rash, or persistent diarrhea.

Levoxa is contraindicated in individuals with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any of its excipients. It should also be avoided in patients with a history of tendon disorders related to fluoroquinolone use, and used with extreme caution in those with uncontrolled epilepsy, myasthenia gravis, or significant cardiac conduction abnormalities.